Non-small cell lung cancer (NSCLC) is a significant source of morbidity and mortality and remains a significant health problem in the United States. Using 10x Xenium spatial transcriptomic studies, we have identified spatial biomarkers for both EGFR WT and EGFR mutant NSCLC lung cancer patients. The highly multiplexed nature of the Xenium platform allows for the discovery of these spatial biomarkers which cannot be discerned through single-plex immunohistochemistry, bulk RNA-sequencing or even single cell RNA-sequencing. We will discuss the use of spatial transcriptomics in biomarker discovery and translational studies and discuss the unique feature sets captured by spatial transcriptomic assays.
